Home › Compare › NBIO vs STAG

NBIO vs STAG: Dividend Comparison 2026

NBIO yields 666666.67% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBIO wins by $8.275235618773884e+34M in total portfolio value
10 years
NBIO
NBIO
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full NBIO calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — NBIO vs STAG

📍 NBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBIOSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBIO + STAG cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NBIO pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBIO
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, NBIO beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBIO + STAG for your $10,000?

NBIO: 50%STAG: 50%
100% STAG50/50100% NBIO
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

NBIO
No analyst data
Altman Z
-223.9
Piotroski
1/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBIO buys
0
STAG buys
0
No recent congressional trades found for NBIO or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBIOSTAG
Forward yield666666.67% ✓3.44%
Annual dividend / share$2.00 ✓$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3% ✓
Portfolio after 10y$8.275235618773884e+34M$18.3K ✓
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓$462.22
Total dividends collected$8.275075881065991e+34M ✓$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: NBIO vs STAG ($10,000, DRIP)

YearNBIO PortfolioNBIO Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$66,677,367$66,666,666.67$10,665$345.09+$66.67M → NBIO
2$415,506,651,117$415,435,306,334.37$11,364$357.70+$415506.64M → NBIO
3$2,419,908,598,386,268$2,419,464,006,269,573.00$12,098$370.43+$2419908598.37M → NBIO
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$12,869$383.28+$13171697643084.44M → NBIO
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$13,677$396.23+$67004927492790120.00M → NBIO
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$14,524$409.27+$318562277003514871808.00M → NBIO
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$15,411$422.41+$1.415484168853553e+24M → NBIO
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$16,339$435.61+$5.878130573362507e+27M → NBIO
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$17,311$448.89+$2.2813793009840744e+31M → NBIO
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$18,327$462.22+$8.275235618773884e+34M → NBIO

NBIO vs STAG: Complete Analysis 2026

NBIO — Stock

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Full NBIO Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this NBIO vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBIO vs SCHDNBIO vs JEPINBIO vs ONBIO vs KONBIO vs MAINNBIO vs PLDNBIO vs EQRNBIO vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.